Background. The activation of NF‐kappa B (NF/kB) signaling pathway plays an important role in the process of epithelial‐mesenchymal transition (EMT) and renal interstitial fibrosis (RIF) in renal tubules. The process of oxidative stress reaction in kidney is via excessive reactive oxygen species (ROS) production to activate NF/kB signaling pathway. Qingshen Granule (QSG) is an effective Chinese formula utilized to treat chronic renal failure. Previous studies confirmed that QSG could inhibit RIF in unilateral ureteral obstruction (UUO) rats. In this study, we used UUO rats to investigate the effects of QSG on oxidative stress and the activation of NF/kB signaling. Seventy male Sprague‐Dawley (SD) rats were randomly divided into a sham group, UUO model group, Qingshen Granules (QSG) high‐dose, medium‐dose, and low‐dose groups, PDTC group, and candesartan group (10 rats in each group). Our study demonstrated that oxidative stress‐NF/kB signal pathway contributed to the formation of UUO renal interstitial fibrosis. QSG may protect against RIF by inhibiting the oxidative stress‐NF/kB signal pathway, reducing inflammation, and improving renal tubular EMT.
5 June 2025 in International Journal of Molecular Medicine
Lactate, traditionally overlooked as a glycolytic byproduct, has recently been recognized for its significant biological roles. The normal kidney plays an essential role in maintaining systemic glucose and lactate homeostasis. Lactylation, as a new epigenetic modification, influences the initiation and progression of kidney diseases through the regulation of gene transcription and cellular metabolism. The present review summarizes current perspectives on the physiological functions of lactate and its renal metabolism, analyzes the roles of lactate and lactylation in acute kidney injury, diabetic nephropathy and chronic kidney disease, and proposes that targeted modulation of lactate metabolism may represent a promising therapeutic strategy for kidney disorders, thereby providing a foundation for future investigations.
2 July 2019 in Evidence-Based Complementary and Alternative Medicine
Objectives. This study investigates the effect of Qingshen Granules (QSG) on chronic renal failure patients and the HIF-1α/Wnt/β-catenin signaling pathway. Methods. Subjects were randomly divided into treatment and control groups, with 42 patients in each group. Participants in the treatment group received 10 g oral doses of QSG 3 times a day, for 12 weeks, whereas subjects in the control group were given a placebo. The effective rates of traditional Chinese medicine (TCM) symptom, serum creatinine (Scr), and estimate glomerular filtration rate (eGFR) as well as the serum levels of HIF-1α, Wnt1, β-catenin, α-SMA, and E-cadherin were evaluated. Results. Eighty patients completed the treatment program and two dropped out. After 12 weeks, the effective rates of TCM symptom and eGFR were found to be higher in the treatment group than in the control group, with statistically significant differences (P = 0.024 and 0.019, respectively). Meanwhile, lower levels of HIF-1α, Wnt1, β-catenin, α-SMA, and E-cadherin were detected in the treatment group, and the differences were statistically significant (P ≤ 0.001, P = 0.001, P ≤ 0.001, P ≤ 0.001, and P = 0.039). No adverse events occurred during the study. Conclusions. QSG can alleviate the clinical symptoms of chronic renal failure (CRF) and protect renal function in patients by influencing the HIF-1α/Wnt/β-catenin signaling pathway. The treatment exhibits no adverse effects and is thus safe to be used by humans.
Histone methylation (HMT), the enzymatic addition of methyl groups to specific histone residues by histone methyltransferases, constitutes a key regulatory mechanism in gene expression and post-translational modulation. Although studies have explored HMT's role in oncogenesis and other organ-specific disorders, HMT is now implicated in the pathogenesis of kidney diseases. A broad spectrum of experimental models, including both in vivo and in vitro systems, has demonstrated the involvement of HMT alterations in diverse renal pathologies such as acute kidney injury, renal fibrosis, diabetic nephropathy, lupus nephritis, polycystic kidney disease, kidney stones, renal cell carcinoma, and immunoglobulin A nephropathy. Targeted modulation of HMT has been associated with attenuated disease progression across these conditions. This review synthesizes current insights into HMT's mechanistic roles in renal pathology and delineates its therapeutic potential as a strategic intervention in kidney disease management.
Chronic kidney disease (CKD) is a systemic disorder in which sarcopenia serves as a critical driver of frailty and mortality. However, the “kidney-muscle axis” remains conceptually fragmented, often confounded by the overlapping definitions of protein-energy wasting (PEW) and cachexia. This review argues that CKD-associated sarcopenia is not driven by isolated myokines, but rather by a clearance-distorted, inflammation-coupled signaling network. We first disambiguate sarcopenia from PEW and cachexia, distinguishing canonical myokines from mediators whose interpretive value is altered by uremia. We then propose a framework organized around four pillars: hypercatabolism, anabolic resistance, mitochondrial dysfunction and bioenergetic remodeling, and context-dependent inflammatory signaling. Within this context, we reinterpret key mediators, including myostatin, growth differentiation factor 15 (GDF-15), insulin-like growth factor 1 (IGF-1), irisin, and interleukin-6 (IL-6), emphasizing that their circulating levels reflect a complex entanglement of altered secretion, impaired renal clearance, and tissue-specific resistance. While the kidney-to-muscle vector is well-supported, direct muscle-to-kidney feedback remains less established. By framing myokine dysregulation as a mechanistic interface, this review aims to refine causal inference and support the development of targeted therapies for muscle wasting in CKD.
Purpose: Kidney disease represents a significant public health burden. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed as antihyperglycemic agents, have demonstrated substantial renoprotective effects and emerged as a focal point in kidney disease research. This study aims to conduct a bibliometric analysis to evaluate the current state, research priorities, and evolving trends in SGLT2 inhibitor studies within the context of kidney disease. Methods: Relevant literature on “SGLT2 inhibitors” and “kidney diseases” was extracted from the Web of Science Core Collection, and the PubMed database was used to search for and supplement clinical research trend analysis. Bibliometric analyses and scientific visualizations were performed using R-bibliometrix, CiteSpace, and VOSviewer software to map the global research landscape. Results: A total of 1,561 publications published between 2009 and 2025 were analyzed. The annual number of publications has increased steadily. The United States is a core contributing country in this field, with strong international collaboration networks. Key institutional contributors include the University of Toronto and the University of Groningen, while prolific authors like Heerspink HJL and Wheeler DC are key contributors in this domain. Core journals are primarily concentrated in the domains of diabetes, nephrology, cardiovascular medicine, and metabolism, with the New England Journal of Medicine exerting the greatest influence. Research focus has evolved from glycemic control to multi-organ protective effects, with study populations expanding to include patients with non-diabetic CKD. Mechanistic investigations now extend to pathways involving inflammation, oxidative stress, and ferroptosis. Conclusion: SGLT2 inhibitors hold considerable promise in the management of kidney disease. Future research directions are expected to emphasize elucidating their underlying mechanisms, evaluating long-term safety, and developing personalized treatment strategies.